AAAAAA

   
Results: 1-14 |
Results: 14
Insulin resistance: definition and consequences
Authors: Lebovitz, HE
Citation: He. Lebovitz, Insulin resistance: definition and consequences, EXP CL E D, 109, 2001, pp. S135-S148
Oral therapies for diabetic hyperglycemia
Authors: Lebovitz, HE
Citation: He. Lebovitz, Oral therapies for diabetic hyperglycemia, END METAB C, 30(4), 2001, pp. 909
Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function
Authors: McFarlane, SI Chaiken, RL Hirsch, S Harrington, P Lebovitz, HE Banerji, MA
Citation: Si. Mcfarlane et al., Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function, DIABET MED, 18(1), 2001, pp. 10-16
Insulin resistance and its treatment by thiazolidinediones
Authors: Lebovitz, HE Banerji, MA
Citation: He. Lebovitz et Ma. Banerji, Insulin resistance and its treatment by thiazolidinediones, REC PROG H, 56, 2001, pp. 265-294
Rosiglitazone monotherapy is effective in patients with type 2 diabetes (vol 86, pg 280, 2001)
Authors: Lebovitz, HE Dole, JF Patwardhan, R Rappaport, EB Freed, MI
Citation: He. Lebovitz et al., Rosiglitazone monotherapy is effective in patients with type 2 diabetes (vol 86, pg 280, 2001), J CLIN END, 86(4), 2001, pp. 1659-1659
Rosiglitazone monotherapy is effective in patients with type 2 diabetes
Authors: Lebovitz, HE Dole, JF Patwardhan, R Rappaport, EB Freed, MI
Citation: He. Lebovitz et al., Rosiglitazone monotherapy is effective in patients with type 2 diabetes, J CLIN END, 86(1), 2001, pp. 280-288
A symposium: The postprandial state: Managing its atherogenic potential - Introduction
Authors: Lebovitz, HE
Citation: He. Lebovitz, A symposium: The postprandial state: Managing its atherogenic potential - Introduction, AM J CARD, 88(6A), 2001, pp. 1H-3H
Effect of the postprandial state on nontraditional risk factors
Authors: Lebovitz, HE
Citation: He. Lebovitz, Effect of the postprandial state on nontraditional risk factors, AM J CARD, 88(6A), 2001, pp. 20H-25H
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
Authors: Fujioka, K Seaton, TB Rowe, E Jelinek, CA Raskin, P Lebovitz, HE Weinstein, SP
Citation: K. Fujioka et al., Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus, DIABET OB M, 2(3), 2000, pp. 175-187
Insulin secretagogues: old and new
Authors: Lebovitz, HE
Citation: He. Lebovitz, Insulin secretagogues: old and new, DIABET REV, 7(3), 1999, pp. 139-153
Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes
Authors: Lebovitz, HE
Citation: He. Lebovitz, Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes, DIABET CARE, 22, 1999, pp. C41-C44
Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men
Authors: Banerji, MA Faridi, N Atluri, R Chaiken, RL Lebovitz, HE
Citation: Ma. Banerji et al., Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men, J CLIN END, 84(1), 1999, pp. 137-144
Type 2 diabetes: An overview
Authors: Lebovitz, HE
Citation: He. Lebovitz, Type 2 diabetes: An overview, CLIN CHEM, 45(8B), 1999, pp. 1339-1345
Type 2 diabetes: An overview
Authors: Lebovitz, HE
Citation: He. Lebovitz, Type 2 diabetes: An overview, CLIN CHEM, 45(8), 1999, pp. 1339-1346
Risultati: 1-14 |